pyrazines has been researched along with Local Neoplasm Recurrence in 164 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 56 (34.15) | 29.6817 |
| 2010's | 84 (51.22) | 24.3611 |
| 2020's | 24 (14.63) | 2.80 |
| Authors | Studies |
|---|---|
| Cimino, G; Cipollone, E; Ortu La Barbera, E; Ottone, T; Perrone, S; Scerpa, MC; Siniscalchi, R; Viola, F; Voso, MT | 1 |
| Brown, JR; Byrd, JC; Cheung, J; Eyre, TA; Furman, RR; Ghia, P; Hamdy, A; Hillmen, P; Izumi, R; Pagel, JM; Patel, P; Schuh, A; Wang, MH; Wierda, WG; Xu, Y | 1 |
| Thol, F | 1 |
| Classe, JM; Ferron, G; Floquet, A; Freyer, G; Hardy-Bessard, AC; Kurtz, JE; Lécuru, F; Motte-Rouge, T; Pautier, P | 1 |
| Black, GS; Byrd, JC; Huang, X; Marth, GT; Misra, S; Qiao, Y; Rogers, KA; Stephens, DM; Tarapcsak, S; Woyach, JA | 1 |
| Budde, LE; Calvo, R; Champion, R; Coleman, M; Geethakumari, PR; Higgins, K; Lam, S; Levy, MY; Lossos, IS; Ma, S; Patti, C; Strati, P | 1 |
| Aasen, SN; Bjørnstad, OV; Haan, C; Herdlevær, CF; Hoang, T; Preis, J; Reigstad, A; Rigg, E; Sundstrøm, T; Thorsen, F | 1 |
| Asada, N; Ennishi, D; Fujii, K; Fujii, N; Fujiwara, H; Kondo, K; Kondo, T; Maeda, Y; Matsubara, C; Matsumura, A; Matsuoka, KI; Nishimori, H; Terao, T; Ueda, H | 1 |
| Saleh, N | 1 |
| Casasnovas, O; Damaj, G; Davies, A; Doorduijn, JK; Dupuis, J; Długosz-Danecka, M; Eek, R; Frigault, MM; Goy, A; Izumi, R; Jacobsen, E; Jain, P; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Nguyen, D; Oberic, L; Panizo, C; Patel, P; Robak, T; Rule, S; Shah, B; Smith, SD; Wang, M; Yin, M; Zinzani, PL | 1 |
| Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
| Sidaway, P | 1 |
| Accordi, B; Basso, G; Bresolin, S; Cortese, G; Mariotto, E; Porcù, E; Serafin, V; Veltri, G | 1 |
| Awan, FT; Barrientos, J; Brown, JR; Burke, K; Byrd, JC; Chaves, JM; Covey, T; Devereux, S; Frigault, MM; Furman, RR; Ghia, P; Gulrajani, M; Hamdy, A; Hillmen, P; Izumi, R; Martin, P; O'Brien, S; Pagel, JM; Patel, P; Rothbaum, W; Schuh, A; Stephens, DM; Wang, MH; Wierda, WG; Woyach, JA | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Ahn, MJ; Cantarini, M; Cho, BC; Frewer, P; Han, JY; Kim, SW; Kowalski, D; Lee, JS; Mellemgaard, A; Orlov, S; Ottesen, L; Ou, X; Oxnard, G; Sequist, LV; Su, WC; Verheijen, RB; Yang, JC; Yu, H | 1 |
| Alsadhan, A; Bibikova, E; Cheung, J; Covey, T; Gaglione, EM; Gulrajani, M; Hamdy, A; Herman, SEM; Izumi, R; Nierman, P; Patel, P; Sun, C; Wiestner, A | 1 |
| Bhargava, P; Danilov, AV; Dyer, MJS; Fegan, CD; Herbaux, C; Hillmen, P; Huang, X; Humeniuk, R; Jürgensmeier, JM; Karlin, L; Kio, EA; Mitra, SS; Rule, SA; Walter, HS; Yi, PC; Zhou, Z | 1 |
| Kim, RS; Shields, CL; Wilde, LR; Yaghy, A | 1 |
| Chishaki, R; Ito, T; Kida, M; Kido, M; Kuraoka, K; Kuroda, Y | 1 |
| Gul, E; Gyger, M; Jazubowiak, A; Kaufman, J; Khan, S; Lau, A; Le, LW; LeBlanc, R; Li, Z; Paul, H; Trudel, S; White, D | 1 |
| Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Ando, K; Ennishi, D; Hayashi, N; Ichikawa, S; Iizumi, S; Izutsu, K; Kato, K; Kawasumi, H; Kumagai, K; Murayama, K; Nagai, H; Patel, P; Shibayama, H; Suzumiya, J; Yamamoto, K | 1 |
| Aladjem, MI; Beck, E; Ceribelli, M; Chen, L; Dahmen, H; Desai, P; Elenbaas, B; Figg, WD; Itkin, Z; Khan, J; Kim, S; Kindrick, JD; Klumpp-Thomas, C; Lee, MJ; Lee, S; McKnight, C; Michael, S; Nichols, S; Peer, CJ; Pommier, Y; Puc, J; Rajapakse, VN; Redon, CE; Schultz, CW; Sciuto, L; Shimellis, H; Steinberg, SM; Sun, Y; Takahashi, N; Thomas, A; Thomas, CJ; Travers, J; Trepel, JB; Varonin, J; Wei, JS; Wilson, KM; Yuno, A; Zenke, FT; Zhang, X; Zhang, Y; Zimmermann, A | 1 |
| Cash, T; Fox, E; Liu, X; Minard, CG; Reid, JM; Scheck, AC; Weigel, BJ; Wetmore, C | 1 |
| Best, S; Danilov, AV; Kittai, A; Lam, V; Liu, T; Orand, K; Spurgeon, SE | 1 |
| Burke, KA; Carnevalli, LS; Cheung, J; Clevenger, TN; Collins, GP; Cunningham, D; Dougherty, BA; Flinn, I; Fox, CP; Frigault, MM; Goy, A; Gribben, J; Hamdy, A; Harrington, EA; Izumi, R; MacDonald, A; Nowakowski, GS; Nuttall, B; Pease, JE; Raymond, A; Roschewski, M; Schalkwijk, S; Stetson, D; Tao, L; Vallurupalli, A; Vose, JM; Willis, B; Yang, B | 1 |
| Annunziata, CM; Bagheri, MH; Botesteanu, DA; Ekwede, I; Harrell, MI; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Merino, MJ; Minasian, L; Nair, J; Steinberg, SM; Swisher, EM; Trepel, JB; Zimmer, A | 1 |
| Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G | 1 |
| Bahceci, E; Iida, H; Kaneko, M; Kobayashi, Y; Kusano, M; Miyamoto, T; Miyawaki, S; Morita, S; Naoe, T; Sakura, T; Takeshita, S; Usuki, K; Yamada, S | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Abildgaard, N; Ahlberg, L; Andersen, NF; Blimark, C; Carlson, K; Dahl, IM; Forsberg, K; Gedde-Dahl, T; Gimsing, P; Gregersen, H; Gruber, A; Guldbrandsen, N; Haukås, E; Hjertner, O; Kvam, AK; Laane, E; Lenhoff, S; Lindås, R; Mellqvist, UH; Nahi, H; Remes, K; Steingrimsdottir, H; Turesson, I; Waage, A; Westin, J | 1 |
| Hatano, Y; Ikeda, S; Ito, M; Nara, M; Oshima, K; Sawada, K; Seto, M; Tagawa, H; Teshima, K; Watanabe, A | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM | 1 |
| Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Attal, M; Bladé, J; Cakana, A; Cavo, M; Desai, A; Esseltine, DL; Goldschmidt, H; Lahuerta, JJ; Liu, K; Lokhorst, HM; Moreau, P; Rosiñol, L; Sonneveld, P; Tacchetti, P; van de Velde, H; Zamagni, E | 1 |
| Alsina, M; Coutre, SE; Gasparetto, C; Khan, M; Lonial, S; Mukhopadhyay, S; Ondovik, MS; Paley, CS; Richardson, PG; Schlossman, RL; Weber, DM | 1 |
| Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR | 1 |
| Childs, R; Cook, L; Jaffe, ES; Ramos, C; Vo, P | 1 |
| Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C | 1 |
| Guzman, ML; Hayslip, J; Howard, DS; Jordan, CT; Liesveld, J; Phillips, GL; Weiss, H | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E | 1 |
| Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K | 1 |
| Bai, Q; Chen, X; Liang, R; Liu, H; Liu, L; Liu, M; Shi, B; Tian, D; Zhang, Y | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Furtado, M; Johnson, R; Kruger, A; Rule, S; Turner, D | 1 |
| Beksac, M; Bengoudifa, BR; Binlich, F; Bladé, J; Cavenagh, JD; Chen, W; Chuncharunee, S; Corradini, P; Corrado, C; de la Rubia, J; Dimopoulos, MA; Einsele, H; Elghandour, A; Gimsing, P; Günther, A; Hou, J; Hungria, VT; Jedrzejczak, WW; Kaufman, JL; LeBlanc, R; Lee, JH; Lee, JJ; Lonial, S; Moreau, P; Nahi, H; Nakorn, TN; Numbenjapon, T; Ocio, EM; Pulini, S; Qiu, L; Richardson, PG; Salwender, H; San-Miguel, JF; Schlossman, RL; Shelekhova, T; Siritanaratkul, N; Sohn, SK; Sopala, M; Tan, D; Veskovski, L; Wang, MC; Warzocha, K; White, D; Yong, K; Yoon, SS | 1 |
| Anderson, KC; Ataman, O; Beksac, M; Benboubker, L; Couturier, C; Dimopoulos, MA; Facon, T; Feng, H; Orlowski, RZ; Potamianou, A; Richardson, PG; Roddie, H; Sonneveld, P; van de Velde, H | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Ahn, JS; Ahn, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH | 1 |
| Armenteros, E; Downward, J; Herledan, G; Kumar, M; Lach, A; Percy, L; Smith, D; Stubbs, M; Yong, K | 1 |
| Arnulf, B; Deraedt, W; Esseltine, DL; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, P; van de Velde, H | 1 |
| Abe, Y; Achira, M; Ando, K; Iizuka, K; Kojima, M; Kuroda, J; Maruyama, D; Ogura, M; Suzuki, K; Suzuki, T; Taniwaki, M; Tobinai, K | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Oza, A; Rajkumar, SV | 1 |
| Agrawal, N; Buxton, A; Chen, L; Cole, PD; De Alarcon, PA; Drachtman, RA; Guillerman, RP; Hogan, SM; Horton, TM; Howard, SC; Liu, H; López-Terrada, D; McCarten, K; Mrazek, MD; Schwartz, CL; Sheehan, AM; Trippet, TM; Voss, S; Wu, MF | 1 |
| Bay, JO | 1 |
| Abdel-Fatah, TM; Aleskandarany, MA; Alsubhi, N; Arora, A; Chan, SY; Curtin, NJ; Doherty, R; Ellis, IO; Green, AR; Madhusudan, S; Martin, SG; Middleton, F; Moseley, PM; Rakha, EA; Stephens, P | 1 |
| Brandalise, SR; Cardinalli, I; de Castro, M; Fedatto, PF; Leal, LF; Marco Antonio, DS; Martinelli, CE; Mastellaro, MJ; Neder, L; Peixoto Lira, RC; Ramalho, L; Rauber Antonini, SR; Scrideli, CA; Seidinger, AL; Tone, LG; Tucci, S; Yunes, JA | 1 |
| Akkari, L; Bowman, RL; Holland, EC; Huse, JT; Joyce, JA; Quail, DF; Quick, ML; Schuhmacher, AJ; Sutton, JC | 1 |
| Bazarbachi, A; Hatoum, HA; Mahfouz, RA; Otrock, ZK; Salem, ZM; Tawil, A; Zaatari, GS | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Golenkov, AK; Mitina, TA | 1 |
| Braiteh, F; Giralt, SA; Hymes, SR; Jones, R | 1 |
| Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S | 1 |
| Battleman, DS; LeBlanc, A; Richardson, PG; Schuster, M; Walters, IB; Wolf, J | 1 |
| Plosker, GL | 1 |
| Bao, L; Huang, XJ; Lu, XJ; Zhang, XH | 1 |
| Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Gonen, M; Gordon, L; Hamelers, R; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, JJ; Zelenetz, AD | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Kastritis, E; Katodritou, E; Michalis, E; Pouli, A; Terpos, E; Tsiftsakis, E; Tsionos, K; Verrou, E; Zervas, K | 1 |
| Knauf, WU; Kornacker, M; Otremba, B; Overkamp, F | 1 |
| Czuczman, MS; Dave, SS; Dunleavy, K; Grant, N; Jaffe, ES; Janik, JE; Pittaluga, S; Shovlin, M; Staudt, LM; Wilson, WH; Wright, G | 1 |
| Amato, AA; Anderson, KC; Avigan, DE; Briemberg, HR; Chanan-Khan, AA; Doss, D; Esseltine, DL; Hassoun, H; Heffner, LT; Kesari, S; Kuter, DJ; Lonial, S; Mitsiades, C; Munshi, NC; Oaklander, AL; Richardson, PG; Schlossman, RL; Weller, E; Wen, PY; Xie, W | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Aghajanian, C; Blessing, JA; Darcy, KM; DeGeest, K; Mannel, RS; Reid, G; Riordan, W; Rotmensch, J; Rubin, SC; Schilder, RJ | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Chang, H; Hsiao, SC; Pei, SN; Wang, MC | 1 |
| Richards, T; Weber, D | 1 |
| Burt Nabors, L; Carson, KA; Desideri, S; Grossman, SA; Lesser, G; Mikkelsen, T; Olson, JJ; Phuphanich, S; Rosenfeld, S; Supko, JG | 1 |
| Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS | 1 |
| Brocca, CM; Coppi, MR; Giannotta, A; Loseto, G; Mele, G; Melpignano, A; Pinna, S; Quarta, G | 1 |
| Gleason, C; Kaufman, J; Lonial, S | 1 |
| Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL | 1 |
| Engelhardt, M; Felthaus, J; Follo, M; Hein, M; Ihorst, G; Ngo, BT; Wäsch, R; Wider, D | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP | 1 |
| Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F | 1 |
| Candoni, A; De Muro, M; De Stefano, V; Ferrara, F; Fianchi, L; Galieni, P; Gozzetti, A; Leone, G; Musto, P; Pagano, L; Petrucci, MT; Pogliani, EM; Pulsoni, A; Specchia, G; Valentini, CG; Venditti, A; Visani, G; Visco, C | 1 |
| Arnulf, B; Asli, B; Belhadj, K; Bories, JC; Bouscary, D; Brouet, JC; Chandesris, O; Choquet, S; Fermand, JP; Ghez, D; Hermine, O; Karlin, L; Macro, M; Malphettes, M; Porcher, R; Soulier, J | 1 |
| Amiot, M; Boccadoro, M; Cavallo, F; Descamps, G; Facon, T; Harousseau, JL; Hulin, C; Leleu, X; Mignard, D; Moreau, P | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Nexø, BA; Vangsted, AJ; Vogel, U | 1 |
| Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A | 1 |
| Bearden, J; Butler, W; Chen, CS; Garrett-Mayer, E; Golshayan, A; Kraft, AS; Lilly, M; Wahlquist, AE | 1 |
| Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME | 1 |
| Beaven, AW; Feldman, T; Ferraro, M; Ford, P; Goy, A; Ivanova, A; Moore, DT; Shea, TC; Smith, J | 1 |
| An, N; Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP | 1 |
| Chen, WM; Chen, XQ; Hou, J; Huang, XJ; Jin, J; Li, Y; Liu, ZG; Shen, ZX; Yuan, ZG | 1 |
| Chang, H; Chen, MH; Qi, C; Reece, D | 1 |
| Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS | 1 |
| Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Arnulf, B; Cakana, A; Deraedt, W; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Moreau, P; Pylypenko, H; van de Velde, H | 1 |
| Bhaskar, B; Kassim, A; Paton, VE; Wamstad, K; White, D; Yi, J | 1 |
| Anderson, KC; Avet-Loiseau, H; Casassus, P; Decaux, O; Facon, T; Garderet, L; Godmer, P; Gouraud, W; Hulin, C; Lodé, L; Magrangeas, F; Marit, G; Minvielle, S; Moreau, P; Munshi, NC; Randriamalala, E; Stoppa, AM; Tiab, M; Voillat, L; Voog, E | 1 |
| Bosly, A; Bouabdallah, R; Boue, F; Bron, D; Casasnovas, O; Coiffier, B; Delarue, R; Feugier, P; Haioun, C; Offner, F; Ribrag, V; Tilly, H | 1 |
| Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C | 1 |
| Chen, LT; Chen, SH; Chen, TJ; Hsing, CH; Huang, HY; Lee, HH; Lee, SW; Li, CF; Lin, CY; Lin, LC; Pan, HY; Sheu, MJ; Shiue, YL; Tian, YF | 1 |
| Fine, H; Hess, K; Jaeckle, K; Kunschner, LJ; Kyritsis, AP; Yung, WK | 1 |
| Dai, G; Wang, X | 1 |
| Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S | 1 |
| Berenson, JR; Schenkein, D; Vescio, R; Yang, HH | 1 |
| Adamson, PC; Berg, SL; Bernstein, M; Blaney, SM; Ginsberg, J; Horton, T; Kitchen, B; Krailo, M; Neville, K | 1 |
| Jung, W; Schroers, R; Zettl, F | 1 |
| Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J | 1 |
| Berdel, WE; Bisping, G; Kienast, J; Kropff, MH; Tchinda, J; Volpert, S; Wenning, D | 1 |
| Adams, J; Camphausen, K; Chang, AA; Chen, Z; Conley, BA; Druzgal, CH; Elsayed, YA; Gius, D; Lebowitz, PF; Mitchell, JB; Morris, JC; Rudy, SF; Sausville, EA; Sunwoo, JB; Van Waes, C | 1 |
| Chanan-Khan, A; Miller, KC | 1 |
| Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T | 1 |
| Aghajanian, C; Dizon, DS; Dupont, J; Raizer, JJ; Sabbatini, P; Spriggs, DR | 1 |
| Alexanian, R; Alsina, M; Anderson, K; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, S; Niesvizky, R; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, DT; Singhal, S; Srkalovic, G; Trehu, E | 1 |
| Adams, J; Berenson, JR; Jarutirasarn, SG; Lee, SP; Mapes, R; Morrison, B; Purner, M; Sadler, K; Schenkein, D; Swift, R; Vescio, RA; Wilson, J; Yang, HH | 1 |
| Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Irwin, DH; Jagannath, S; Rajkumar, SV; Richardson, PG; Singhal, S; Srkalovic, G | 1 |
| Laurie, SA; Licitra, L | 1 |
| Richardson, P | 1 |
| Alloro, E; Brocca, MC; Coppi, MR; Mele, G; Pinna, S; Quarta, G | 1 |
| Belch, A; Crump, M; Eisenhauer, EA; Gascoyne, RD; Klasa, R; Kouroukis, CT; Powers, J; Sehn, L; Wright, J | 1 |
| Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; O'Connor, OA; Robertson, MJ; Shi, H; Stadtmauer, EA | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Bo, J; Da, WM; Gao, CJ; Huang, WR; Jing, Y; Li, R; Wang, QS; Wu, XX; Yu, L; Zhang, YZ | 1 |
| Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P | 1 |
| Chen, CI; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ | 1 |
| Boccadoro, M; Bruno, B; Carnevale-Schianca, F; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Atkins, JN; Chansky, K; Crowley, JJ; Davies, AM; Farneth, N; Franklin, WA; Gandara, DR; Guaglianone, PP; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J | 1 |
| Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
| Etxebarria, J; Hernández, E; Lopez, O; Mateos-Mazon, J; Pérez-Simón, JA; San Miguel, JF | 1 |
| Coleman, RL; Gershenson, DM; Johnston, TA; Landen, CN; Levenback, C; Milam, MR; Ramirez, PT | 1 |
| Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG | 1 |
| Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R | 1 |
| Cavenagh, JD; Davies, FE; Jackson, GH; Morgan, GJ | 1 |
| Lonial, S | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Kami, M; Tsubokura, M | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O | 1 |
| Dimopoulos, MA; Roussou, M; Terpos, E | 1 |
23 review(s) available for pyrazines and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines | 2021 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Waldenstrom macroglobulinemia: prognosis and management.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2008 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide | 2010 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2009 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide | 2010 |
[Development of bladder cancer chemoprevention].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Papillary; Humans; Neoplasm Recurrence, Local; Piroxicam; Pyrazines; Retinoids; Thiones; Thiophenes; Urinary Bladder Neoplasms | 2003 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide | 2006 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
Position statement on the use of bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Bortezomib in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2008 |
75 trial(s) available for pyrazines and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2021 |
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2022 |
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pyrazines; Time Factors; Treatment Outcome | 2019 |
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Salvage Therapy; Survival Rate; Triazines | 2020 |
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines | 2020 |
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Purines; Pyrazines; Pyrimidines; Quinazolinones; Salvage Therapy; Tissue Distribution | 2020 |
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Imidazoles; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2021 |
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Headache; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Purpura; Pyrazines; Survival Analysis; Treatment Outcome | 2021 |
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Topics: Adolescent; Central Nervous System Neoplasms; Checkpoint Kinase 1; Checkpoint Kinase 2; Child; Child, Preschool; Female; Humans; Leukopenia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Thrombocytopenia; Young Adult | 2021 |
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Pyrazines; Receptors, Antigen, B-Cell; Syk Kinase | 2022 |
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Topics: B-Lymphocytes; Benzamides; Humans; Morpholines; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Pyrimidines | 2021 |
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult | 2018 |
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Axl Receptor Tyrosine Kinase; Creatine Kinase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Thrombocytopenia; Treatment Outcome | 2018 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate | 2019 |
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2013 |
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Pyrazines | 2013 |
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Salvage Therapy; Survival Rate; Vorinostat | 2013 |
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2013 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prognosis; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2014 |
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate | 2015 |
Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Topics: Administration, Cutaneous; Administration, Intravenous; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Renal Insufficiency; Treatment Outcome | 2015 |
Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Interleukin-6; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2015 |
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Disease-Free Survival; Hodgkin Disease; Humans; Ifosfamide; Neoplasm Recurrence, Local; Pyrazines; Vinblastine; Vinorelbine; Young Adult | 2015 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Treatment Outcome | 2008 |
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Remission Induction | 2009 |
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cystatin C; Female; Humans; Immunoassay; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Germany; Hematology; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Physicians' Offices; Pyrazines; Secondary Prevention; Treatment Outcome | 2009 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Young Adult | 2009 |
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2010 |
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab | 2011 |
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines | 2011 |
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Radioimmunotherapy; Salvage Therapy; Survival Rate | 2012 |
Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines | 2011 |
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2012 |
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2012 |
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2013 |
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Survival Rate | 2013 |
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome | 2002 |
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Safety; Treatment Outcome | 2003 |
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Topics: Biological Availability; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms; Probability; Proportional Hazards Models; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Risk Assessment; Salvage Therapy; Survival Rate; Treatment Outcome | 2004 |
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2005 |
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors | 2005 |
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazines | 2005 |
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Time Factors; Treatment Outcome | 2005 |
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome | 2006 |
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2007 |
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2006 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Boronic Acids; Bortezomib; Canada; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Protease Inhibitors; Pyrazines; Risk Assessment; Salvage Therapy; Severity of Illness Index; Survival Rate; Treatment Outcome; Waldenstrom Macroglobulinemia | 2007 |
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Homologous | 2007 |
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Pyrazines; Remission Induction; Risk Assessment; Survival Analysis | 2006 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2007 |
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Proteasome Inhibitors; Pyrazines | 2008 |
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; United States | 2007 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia | 2008 |
67 other study(ies) available for pyrazines and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Topics: Aniline Compounds; Bone Marrow; Brain; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2021 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2022 |
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Melanoma; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines | 2022 |
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2022 |
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2023 |
Gilteritinib Changes AML Landscape.
Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; Drug Approval; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Gilteritinib improves outcomes in AML.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2020 |
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Topics: Aminopyridines; Cell Proliferation; Child; Core Binding Factor Alpha 2 Subunit; Cyclohexylamines; Drug Resistance, Neoplasm; Humans; Indazoles; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrimidines; Syk Kinase; Tumor Cells, Cultured | 2019 |
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
Topics: Administration, Oral; Aniline Compounds; Ciliary Body; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Uveal Neoplasms; Visual Acuity | 2020 |
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyrazines; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2020 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Topics: Aged; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Replication; DNA Topoisomerases, Type I; Genomic Instability; Humans; Isoxazoles; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Small Cell Lung Carcinoma | 2021 |
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome; United States; Young Adult | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Polycomb Repressive Complex 1; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Side-Population Cells; Up-Regulation | 2014 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide | 2013 |
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Interferons; Lymph Nodes; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Rituximab; Transplantation, Homologous | 2013 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Survival Rate | 2014 |
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Matched-Pair Analysis; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Survival Rate | 2015 |
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Genes, ras; Humans; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2015 |
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Checkpoint Kinase 1; Cohort Studies; DNA Repair; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Humans; Indoles; MCF-7 Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Phosphorylation; Protein Kinases; Pyrazines; Pyridones; Radiation Tolerance; RNA Interference; RNA, Small Interfering; Serine; Sulfones; Up-Regulation | 2016 |
IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Androstenedione; Apoptosis; Cell Line, Tumor; Child; Child, Preschool; Dehydroepiandrosterone Sulfate; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Infant; Insulin-Like Growth Factor II; Male; Neoplasm Recurrence, Local; Phosphoproteins; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; Testosterone | 2016 |
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Drug Resistance, Neoplasm; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Insulin-Like Growth Factor I; Macrophages; Mice; Mice, Inbred Strains; Neoplasm Recurrence, Local; Neoplasms, Experimental; NFATC Transcription Factors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Picolinic Acids; Pyrazines; Receptor, IGF Type 1; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; STAT6 Transcription Factor; Tumor Microenvironment | 2016 |
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; T-Lymphocyte Subsets; Transplantation, Autologous; Vincristine | 2008 |
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2008 |
Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Psoriasis; Pyrazines; Remission Induction | 2008 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation | 2009 |
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Boronic Acids; Bortezomib; Doxorubicin; Female; Gene Expression Profiling; Germinal Center; Humans; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Prognosis; Pyrazines; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Polyneuropathies; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Capillary Leak Syndrome; Dexamethasone; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Secondary Prevention | 2010 |
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Frail Elderly; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Treatment Outcome | 2010 |
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Pyrazines; Receptors, Glucocorticoid; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cyclin D1; Cyclin D2; Cyclin D3; DNA; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Polymerase Chain Reaction; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cyclophosphamide; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; DNA, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Pyrazines; Tomography, X-Ray Computed | 2010 |
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2010 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult | 2011 |
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Flow Cytometry; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Survival Rate; Translocation, Genetic | 2011 |
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Denmark; Female; Genetic Association Studies; Humans; Interferon-alpha; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; NF-kappa B p50 Subunit; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Pyrazines; Recombinant Proteins; Survival Analysis; Thalidomide | 2011 |
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Germany; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome | 2010 |
[Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Nucleus; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Pyrazines | 2012 |
Minor clone provides a reservoir for relapse in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosome Aberrations; Clone Cells; Dexamethasone; Disease Progression; Evolution, Molecular; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Pyrazines; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Tumor Suppressor Protein p53 | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Rectal Neoplasms; Retrospective Studies; S-Phase Kinase-Associated Proteins; Survival Rate; Tumor Cells, Cultured | 2013 |
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2003 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Sequence Deletion; Treatment Outcome | 2005 |
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cytokines; Female; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasm Recurrence, Local; NF-kappa B; Protease Inhibitors; Pyrazines; Stomatitis; Transcription Factor RelA | 2005 |
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
Topics: Antineoplastic Agents; Bone Marrow Neoplasms; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2006 |
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Failure | 2007 |
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Salvage Therapy | 2006 |
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
Treatment for elderly patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |